Pro Medicus (ASX:PME) FFO


ASX:PME Pro Medicus Ltd ASX:PME
98 GF Score
Price A$178.99
GF Value A$244.83
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pro Medicus FFO?

FFO (Funds from operations) only applies to REITs.

ASX:PME
98GF Score
Pro Medicus Ltd ASX:PME
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pro Medicus (ASX:PME) Overvalued in 2026?

Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued. The current stock price of A$178.99 is trading 26.9% below its estimated GF Value™ of A$244.83. GuruFocus considers Pro Medicus to be Modestly Undervalued.

Key valuation signals for ASX:PME:

  • FFO:
  • GF Value™: A$244.83 vs. price of A$178.99 (26.9% below fair value)
  • GF Score™: 98/100 with 1 warning sign

No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pro Medicus Business Description

Address 450 Swan Street, Richmond, VIC, AUS, 3121
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score

Get the complete analysis for ASX:PME

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$178.99
Price
A$244.83
GF Value